These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 32456018)

  • 1. Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models.
    Garcia PL; Miller AL; Yoon KJ
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical models of pancreatic ductal adenocarcinoma.
    Krempley BD; Yu KH
    Chin Clin Oncol; 2017 Jun; 6(3):25. PubMed ID: 28705002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models.
    Hoare O; Fraunhoffer N; Elkaoutari A; Gayet O; Bigonnet M; Roques J; Nicolle R; McGuckin C; Forraz N; Sohier E; Tonon L; Wajda P; Boyault S; Attignon V; Tabone-Eglinger S; Barbier S; Mignard C; Duchamp O; Iovanna J; Dusetti NJ
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34069519
    [No Abstract]   [Full Text] [Related]  

  • 4. DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives.
    Stoof J; Harrold E; Mariottino S; Lowery MA; Walsh N
    Front Cell Dev Biol; 2021; 9():749490. PubMed ID: 34712667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo models of pancreatic ductal adenocarcinoma.
    Vudatha V; Herremans KM; Freudenberger DC; Liu C; Trevino JG
    Adv Cancer Res; 2023; 159():75-112. PubMed ID: 37268402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and application of patient-derived xenograft models in pancreatic cancer research.
    Wang CF; Shi XJ
    Chin Med J (Engl); 2019 Nov; 132(22):2729-2736. PubMed ID: 31725451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies.
    Pham TND; Shields MA; Spaulding C; Principe DR; Li B; Underwood PW; Trevino JG; Bentrem DJ; Munshi HG
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33503832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations.
    Ijichi H
    World J Clin Oncol; 2011 May; 2(5):195-202. PubMed ID: 21611096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreas 3D Organoids: Current and Future Aspects as a Research Platform for Personalized Medicine in Pancreatic Cancer.
    Moreira L; Bakir B; Chatterji P; Dantes Z; Reichert M; Rustgi AK
    Cell Mol Gastroenterol Hepatol; 2018 Mar; 5(3):289-298. PubMed ID: 29541683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational and Clinical Relevance of PDX-Derived Organoid Models in Oncology Drug Discovery and Development.
    Kumari R; Xu X; Li HQ
    Curr Protoc; 2022 Jul; 2(7):e431. PubMed ID: 35789132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma.
    Liu Z; Ahn MH; Kurokawa T; Ly A; Zhang G; Wang F; Yamada T; Sadagopan A; Cheng J; Ferrone CR; Liss AS; Honselmann KC; Wojtkiewicz GR; Ferrone S; Wang X
    J Transl Med; 2020 Jun; 18(1):255. PubMed ID: 32580742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions.
    Suri R; Zimmerman JW; Burkhart RA
    Ann Pancreat Cancer; 2020 Dec; 3():. PubMed ID: 33889840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors.
    Romero-Calvo I; Weber CR; Ray M; Brown M; Kirby K; Nandi RK; Long TM; Sparrow SM; Ugolkov A; Qiang W; Zhang Y; Brunetti T; Kindler H; Segal JP; Rzhetsky A; Mazar AP; Buschmann MM; Weichselbaum R; Roggin K; White KP
    Mol Cancer Res; 2019 Jan; 17(1):70-83. PubMed ID: 30171177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?
    Sereti E; Karagianellou T; Kotsoni I; Magouliotis D; Kamposioras K; Ulukaya E; Sakellaridis N; Zacharoulis D; Dimas K
    J Proteomics; 2018 Sep; 188():107-118. PubMed ID: 29398619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
    Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
    United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy.
    Torres MP; Rachagani S; Souchek JJ; Mallya K; Johansson SL; Batra SK
    PLoS One; 2013; 8(11):e80580. PubMed ID: 24278292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.
    Thorel L; Morice PM; Paysant H; Florent R; Babin G; Thomine C; Perréard M; Abeilard E; Giffard F; Brotin E; Denoyelle C; Villenet C; Sebda S; Briand M; Joly F; Dolivet E; Goux D; Blanc-Fournier C; Jeanne C; Villedieu M; Meryet-Figuiere M; Figeac M; Poulain L; Weiswald LB
    J Exp Clin Cancer Res; 2023 Oct; 42(1):260. PubMed ID: 37803448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective.
    Perales-Patón J; Piñeiro-Yañez E; Tejero H; López-Casas PP; Hidalgo M; Gómez-López G; Al-Shahrour F
    Public Health Genomics; 2017; 20(2):81-91. PubMed ID: 28858862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Azmi AS; Khan HY; Muqbil I; Aboukameel A; Neggers JE; Daelemans D; Mahipal A; Dyson G; Kamgar M; Al-Hallak MN; Tesfaye A; Kim S; Shidham V; M Mohammad R; Philip PA
    Clin Cancer Res; 2020 Mar; 26(6):1338-1348. PubMed ID: 31831564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Samples.
    Choi SI; Jeon AR; Kim MK; Lee YS; Im JE; Koh JW; Han SS; Kong SY; Yoon KA; Koh YH; Lee JH; Lee WJ; Park SJ; Hong EK; Woo SM; Kim YH
    Front Oncol; 2019; 9():875. PubMed ID: 31572675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.